Q-omics provides the consensus-scored FBXO45 profile across patient tissues and cancer cell-line models. FBXO45 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, FBXO45 is differentially expressed in 16, with the highest sampling consensus in HNSC. Additionally, FBXO45 RNA expression shows 20,954 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRP, HNSC, and ACC as cancer lineages where FBXO45 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FBXO45 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FBXO45 survival associations across molecular data types. FBXO45 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FBXO45 RNA expression–survival associations across cancer types. High FBXO45 expression shows unfavorable associations in KIRP, LUAD, MESO, KICH, LIHC and ACC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for FBXO45 RNA expression.
This table summarizes FBXO45 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FBXO45. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FBXO45 shows higher tumor expression in HNSC, KIRC, BLCA, LUSC, LUAD and LIHC. The HNSC box plot shows higher FBXO45 RNA expression in tumor versus normal tissue (log2 FC = +1.473, t-test p < 0.001).
This table shows molecular features associated with FBXO45 in patient tissues and cancer cell lines. In patient samples, FBXO45 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FBXO45 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Lymphoma.
